Get Quartz in your inbox

Free daily briefing on global business news.

AstraZeneca is readying its own cancer-targeting drug for regulatory approval after trial win

Sone-Ve cut the risk of death by 42% in a Phase III gastric cancer trial; median survival was 10.6 months versus 6.4

Bloomberg / Getty Images

AstraZeneca $AZN reported Phase III results on Sunday showing that its cancer drug sonesitatug vedotin cut the likelihood of death by 42% among previously treated patients with advanced gastric cancer. The company is preparing to file the drug for regulatory approval, according to The Wall Street Journal.

The drug, known as Sone-Ve, is an antibody-drug conjugate. In the CLARITY-Gastric01 trial, it was compared with investigator's choice of therapy........

© Quartz